OKYO Pharma to Include Additional Analyses in Upcoming Dry Eye Disease Key Opinion Leader Event | NASDAQ:OKYO
Proactive InvestorsApr 9 04:36 ET
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024.
GlobeNewswireApr 8 19:00 ET
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye
OKYO PharmaApr 2 00:00 ET
Borr Drilling, Aehr Test Systems, Airship AI Among Premarket Losers' Pack
Seeking AlphaMar 25 08:41 ET
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
OKYO Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 22 11:15 ET
Express News | HC Wainwright & Co. Maintains Buy on OKYO Pharma, Raises Price Target to $7
Moomoo 24/7Mar 22 11:05 ET
OKYO Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 366.67% HC Wainwright & Co. $6 → $7 Maintains Buy 01/08/2024 233.33% HC Wainwright & Co. $4 → $
BenzingaMar 22 11:04 ET
Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and OKYO Pharma Limited Sponsored ADR (OKYO)
TipRanksMar 22 09:00 ET
Express News | OKYO Pharma Shares Are Trading Higher After the Company's OK-101 Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease in Its First-in-human Phase 2 Trial
Moomoo 24/7Mar 22 07:12 ET
Express News | OKYO Pharma Says OK-101 Achieves Statistical Significance For Multiple Signs And Symptoms Of Dry Eye Disease Including Ocular Pain Relief In Its First-in-Human Phase 2 Trial Of OK-101
Moomoo 24/7Mar 22 07:03 ET
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease Including Ocular Pain Relief in Its First-in-Human Phase 2 Trial of OK-101
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable ben
OKYO PharmaMar 22 00:00 ET
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data From Phase 2 Dry Eye Disease Trial
–Phase 2 OK-101 efficacy data to be released March 22nd, 2024--KOL Event to be held on April 9th, 2024 at 12 PM ET-London and New York, NY, March 21, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clini
OKYO PharmaMar 21 00:00 ET
OKYO Pharma to Release New and Comprehensive Data From Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
–Phase 2 OK-101 efficacy data to be released March 22, 2024-London and New York, NY, March 20, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovati
OKYO PharmaMar 20 00:00 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAinos (NASDAQ:AIMD) stock moved upwards by 54.3% to $1.62 during Friday's after-market session. The company's market cap stands at $7.5 million. Aadi Bioscience (NASDAQ:AADI) shares rose 38.54%
BenzingaMar 1 16:32 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersSeaStar Medical Holding (NASDAQ:ICU) shares rose 27.9% to $1.1 during Monday's pre-market session. The company's market cap stands at $71.6 million. Aesthetic Medical Intl (NASDAQ:AIH) shares i
BenzingaFeb 12 08:05 ET
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index adding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) rose 0.4%.
MT NewswiresFeb 9 13:54 ET
Sector Update: Health Care
Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index adding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) rose 0.5%.
MT NewswiresFeb 9 13:36 ET
FDA Approves OKYO Pharma's IND for NCP Treatment Trial
InvestingFeb 9 10:18 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million. TC BioPharm (Holdings) (NASDAQ:T
BenzingaFeb 9 08:06 ET
OKYO Pharma Gets FDA Clearance for OK-101 Application
By Chris Wack OKYO Pharma said that the U.S. Food and Drug Administration has cleared OK-101 as its first investigational new drug application for the treatment of neuropathic corneal pain. The biop
WSJFeb 9 07:24 ET
No Data
No Data